Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case report

被引：0

作者：

Briane, Aurelie ^{[1
,2
]}

Horvais, Valerie ^{[3
]}

Sigaud, Marianne ^{[2
,4
]}

Trossaert, Marc ^{[2
,4
]}

Drillaud, Nicolas ^{[2
,4
]}

Ternisien, Catherine ^{[2
,4
]}

Fouassier, Marc ^{[2
,4
]}

Babuty, Antoine ^{[2
,4
]}

机构：

[1] Nantes Univ, CHU Nantes, Serv Med Interne, Nantes, France

[2] Nantes Univ, CHU Nantes, Ctr Ressource & Competence Malad Hemorrag Constitu, Nantes, France

[3] Nantes Univ, CHU Nantes, Unite Invest Clin 17, Nantes, France

[4] Nantes Univ, CHU Nantes, Serv Hematol Biol, Nantes, France

来源：

EJHAEM | 2024年 / 5卷 / 05期

关键词：

allo-antibodies; bleeding disorders; emicizumab; haemostasis; von Willebrand disease; FACTOR-VIII CONCENTRATE; ALLOANTIBODIES;

D O I：

10.1002/jha2.984

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment of type 3 von Willebrand disease by infusion of von Willebrand factor (VWF) and factor VIII (FVIII) concentrates may lead to the development of anti-VWF antibodies, challenging haemostasis management. The systematic review of the literature presented here retrieved 15 such cases (surgery n = 11, bleeding n = 4). The heterogeneous patient management mostly involved continuous infusion of FVIII, or recombinant FVIIa together with various other strategies. Off-label infusion of the bispecific monoclonal antibody emicizumab was prescribed in three cases and in a complex local case, ultimately well-controlled with emicizumab. This illustrates the fact that emicizumab appears as a therapeutic option in this context of allo-immunisation.

引用

页码：964 / 970

页数：7

共 50 条

[1] The effect of anti-von Willebrand factor immunoglobulin on assays of von Willebrand factor: A case report
Bowyer, A.
Brown, P.
Hopkins, B.
Lowe, A.
Kitchen, S.
van Veen, J.
Mensah, P.
Maclean, R.
[J]. HAEMOPHILIA, 2019, 25 : 48 - 49
[2] Factor-VIII/von Willebrand factorDevelopment of anti-von Willebrand factor antibodies: case report
[J]. Reactions Weekly, 2018, 1683 (1) : 302 - 302
[3] von Willebrand factor alloantibodies in type 3 von Willebrand disease
Kotnik, Barbara Faganel
Strandberg, Karin
Debeljak, Marusa
Kitanovski, Lidija
Jazbec, Janez
Benedik-Dolnicar, Majda
Bakija, Alenka Trampus
[J]. BLOOD COAGULATION & FIBRINOLYSIS, 2020, 31 (01) : 77 - 79
[4] The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease
Jilma-Stohlawetz, Petra
Knoebl, Paul
Gilbert, James C.
Jilma, Bernd
[J]. THROMBOSIS AND HAEMOSTASIS, 2012, 108 (02) : 284 - 290
[5] The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor
Pergantou, H.
Xafaki, P.
Adamtziki, E.
Koletsi, P.
Komitopoulou, A.
Platokouki, H.
[J]. HAEMOPHILIA, 2012, 18 (03) : e66 - e67
[6] Hypersensitivity to von Willebrand factor and von Willebrand disease: A case-report
Carneiro-Leao, D.
Queiros, R.
Mota, T.
Fernandes, S.
Lopes, M.
Koch, M. D. C.
[J]. HAEMOPHILIA, 2024, 30 : 131 - 132
[7] Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review
Giuffrida, Anna C.
Siboni, Simona M.
Baronciani, Luciano
Poli, Giovanni
Gandini, Giorgio
Peyvandi, Flora
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2024,
[8] Von Willebrand factor inhibitors developed in type 3 von Willebrand disease
Megdiche, F.
Kassar, O.
Hdiji, S.
Mbarek, L.
Charfi, M.
Elloumi, M.
Kallel, C.
[J]. HAEMOPHILIA, 2019, 25 : 87 - 87
[9] The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease
Seaman, Craig D.
Ragni, Margaret, V
[J]. THROMBOSIS AND HAEMOSTASIS, 2020, 120 (08) : 1159 - 1165
[10] von Willebrand disease and von Willebrand factor
Sadler, Brooke
Castaman, Giancarlo
O'Donnell, James S.
[J]. HAEMOPHILIA, 2022, 28 : 11 - 17

← 1 2 3 4 5 →